Neovasc Inc. (Nasdaq: NVCN) reported an 86% successful implantation rate for its Tiara transcatheter mitral valve sending the stock price soaring $1.00 to close at $2.42.
Neovasc provides Tiara implantation rate
December 06, 2016 at 16:22 PM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.